Centrally Acting Therapies for Irritable Bowel Syndrome

被引:40
|
作者
Grover, Madhusudan [2 ]
Drossman, Douglas A. [1 ]
机构
[1] Univ N Carolina, Div Gastroenterol & Heptol, UNC Ctr Funct GI & Motil Disorders, Chapel Hill, NC 27599 USA
[2] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
关键词
Irritable bowel syndrome; Treatment; Psychotropic agents; Antidepressants; Behavioral treatments; RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIOR THERAPY; FUNCTIONAL GASTROINTESTINAL DISORDERS; PLACEBO-CONTROLLED TRIAL; BRAIN-GUT AXIS; DOUBLE-BLIND; TRICYCLIC ANTIDEPRESSANTS; PSYCHOLOGICAL TREATMENT; VISCERAL STIMULATION; RECTAL SENSITIVITY;
D O I
10.1016/j.gtc.2010.12.003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Irritable bowel syndrome (IBS) and other functional gastrointestinal (GI) disorders typically defy traditional diagnostic methods based on structural abnormalities, and has led to the emergence of the discipline of neurogastroenterology or the study of the "brain-gut axis," which is based on dysregulation of neuroenteric pathways as a key pathophysiological feature of IBS. Centrally acting treatments can influence these pathways and improve the clinical manifestations of pain and bowel dysfunction associated with this disorder. To successfully implement these treatment strategies, it is important to recognize their dual effects on brain and gut, understanding the nature and severity of the GI symptoms and their psychosocial concomitants, and applying them within the context of the patient's understanding of their value.
引用
收藏
页码:183 / +
页数:25
相关论文
共 50 条
  • [41] Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome
    Cash, Brooks D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (07) : 1405 - 1415
  • [42] Irritable bowel syndrome; update on pathophysiology and management
    Quigley, Eamonn M. M.
    Craig, Orla F.
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2012, 23 (04) : 313 - 322
  • [43] The use of psychotropic drugs in irritable bowel syndrome
    Dekel, Roy
    Drossman, Douglas A.
    Sperber, Ami D.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (03) : 329 - 339
  • [44] Focus on Pharmacotherapy for Irritable Bowel Syndrome with Constipation
    Liu, Joy J.
    Brenner, Darren M.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2021, 50 (03) : 639 - 653
  • [45] Microbiome and Its Role in Irritable Bowel Syndrome
    Pimentel, Mark
    Lembo, Anthony
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (03) : 829 - 839
  • [46] Treating irritable bowel syndrome with probiotics: the evidence
    Parkes, G. C.
    Sanderson, J. D.
    Whelan, K.
    PROCEEDINGS OF THE NUTRITION SOCIETY, 2010, 69 (02) : 187 - 194
  • [47] Probiotics and irritable bowel syndrome
    Dai, Cong
    Zheng, Chang-Qing
    Jiang, Min
    Ma, Xiao-Yu
    Jiang, Li-Juan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (36) : 5973 - 5980
  • [48] Probiotics in Irritable Bowel Syndrome The Science and the Evidence
    Quigley, Eamonn M. M.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2015, 49 : S60 - S64
  • [49] Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation
    Eswaran, Shanti
    Guentner, Amanda
    Chey, William D.
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2014, 20 (02) : 141 - 151
  • [50] Irritable bowel syndrome and diet
    Weber, H. Christian
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2022, 29 (02) : 200 - 206